

Cerep reports second quarter revenues Company launches two novel Drug discovery tools

Paris, France, 11 August 1999 – Cerep SA (Nouveau Marché: CEREP) today announced second quarter sales for the three-month period ended June 30, 1999.

The French drug discovery company, reported second quarter sales of FF 15.1 million (Euros 2.3 million) compared to FF 15.0 million (Euros 2.3 million) for the same period in 1998. For the first half, the sales were FF 29.9 million (Euros 4.6 million) compared to FF 31.5 million (Euros 4.8 million) for the same period in 1998.

Cerep further announced the launch of two novel and innovative drug discovery tools – BioPrint™ and Odyssey 5000.

BioPrint™

BioPrint™ is a powerful database designed to enhance the discovery and optimisation of lead compounds in the drug discovery process. The database mines information obtained through *in vitro* pharmacological, toxicity, pharmacodynamic profiles and *in vivo* activities of BioPrint™ reference compounds as observed in their development. BioPrint™ enables the pharmaceutical industry to establish molecular-level toxicology and pharmacology profiles and facilitates lead compound and pre-clinical optimisation in drug development and discovery. Pharmaceutical partners will be able to purchase multi-year access to the database and will have access to expanding, non-exclusive database content on marketed drugs and subscribers reference compounds. Moreover, BioPrint™ will also integrate data on an exclusive basis for subscribers proprietary compounds. BioPrint™ will enable pharmaceutical partners to gain insight to some of the less well understood aspects of early stage drug development by providing a rational basis for lead compound and pre-clinical optimisation. Under the terms of the agreement signed with Cerep on July 20, 1999, Bristol-Myers Squibb will be the first subscriber to the BioPrint™ database.

Odyssey 5000

Odyssey 5000 is a diverse lead-seeking library containing 5000 highly pure compounds. It is based on a unique collection of monomer building blocks designed for primary screening in drug discovery programs. The compounds contained in Odyssey 5000 possess the physical and chemical properties currently required in high throughput screening and most commonly demanded by chemists for compounds entering pharmaceutical development.

"We believe that sales of our innovative drug discovery tools will undoubtedly contribute to our future revenues," commented Thierry Jean, President and CEO of Cerep. "The launch of BioPrint™ and Odyssey 5000 reflect the Company's continuing efforts in implementing its business strategy by developing innovative technologies and tools in order to make the drug discovery process more efficient and cost-effective."

Cerep is a drug discovery company that focuses on finding new and effective drugs. The Company's mission is to develop integrated technologies and tools to overcome the current obstacles and challenges of the drug discovery process. Cerep assists pharmaceutical companies by incorporating all the facets of innovative technologies for the discovery of novel and effective drugs. In Europe and North America, the Company has developed an extensive R&D capacity in the areas of high-throughput profiling, lead development and screening, high-throughput organic synthesis and computational chemistry. Cerep has a unique business model combining revenue generating drug discovery services with strategic collaborations in drug discovery.

Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements" for purposes of the safe harbour provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company's proprietary rights and other factors described in the prospectus relating to the company's recent public offering.